Biomarker collaboration with Sahlgrenska University HospitalDate: 2021-02-10
Alzinova is collaborating with prominent researchers at Sahlgrenska University Hospital in Gothenburg, Sweden, to track markers of neurodegenerative change in Alzheimer’s disease.
As part of the ongoing preparations for its upcoming Phase 1b clinical study with therapeutic vaccine (ALZ-101) for the treatment of Alzheimer’s disease, Alzinova has initiated a collaboration with the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. The work will be led by Kaj Blennow and Henrik Zetterberg, world-leading professors in neurochemistry.
The collaboration will focus on measuring and evaluating potential changes in biomarkers associated with Alzheimer’s disease and/or neurodegeneration following multiple immunisations with ALZ-101, as compared to placebo, in study participants with early Alzheimer’s disease.
More specifically, the research will measure:
- Changes in cerebrospinal fluid (CSF) concentrations of amyloid Aβ42, Aβ40, Aβ42/40 ratio, T-tau and P-tau.
- Changes in blood (plasma) and CSF concentrations of NFL.
- Changes in CSF of concentrations of neurogranin, TREM-2 and YKL-40; and possibly other biomarkers related to Alzheimer’s disease and/or neurodegeneration.
Kristina Torfgård, CEO at Alzinova, says, “We are very pleased to be collaborating with Henrik Zetterberg, Kaj Blennow and the distinguished Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. The highly respected and highly cited work Henrik and Kaj are doing is helping to advance the development of biomarkers for neurodegenerative diseases. Such markers are key to furthering our understanding of Alzheimer’s disease diagnosis and progression.”